Kane Biotech Inc.

Kane Biotech Inc.

KNBIF
Kane Biotech Inc.US flagOther OTC
0.02
USD
+0.00
- -
3.47MMarket Cap

Total Valuation

Kane Biotech Inc. carries a market capitalization of 3.47M, placing it among publicly traded companies globally. Its enterprise value stands at 6.75M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.47M
Enterprise Value6.75M

Share Statistics

Kane Biotech Inc. currently has 181.86M shares outstanding.

Shares Outstanding181.86M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 89.20, and the price-to-book ratio stands at -0.53.

PE RatioN/A
PS Ratio89.20
PB Ratio-0.53
P/TBV Ratio-2.66
P/FCF Ratio-2.12
P/OCF Ratio-1.98

Enterprise Valuation

EV / Sales115.19
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Kane Biotech Inc. maintains a current ratio of 0.45, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -135.17, indicating conservative leverage, while an interest coverage ratio of -8.31 demonstrates limited ability to service its debt obligations.

Current Ratio0.45
Quick Ratio0.16
Debt / Equity-135.17
Debt / EBITDA-0.94
Interest Coverage-8.31

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-97.12
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover0.33

Taxes

Income Tax4,223.00
Effective Tax RateN/A

Stock Price Statistics

Kane Biotech Inc.'s stock has declined approximately -51.71429% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.03.

Beta (5Y)N/A
52-Week Price Change-51.71429%
50-Day Moving Average0.02
200-Day Moving Average0.03
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Kane Biotech Inc. generated 58,574.00 in revenue and converted that into -2.22M in net income, yielding earnings per share of -0.01. EBITDA reached -2.03M, while operating income came in at -2.17M.

Revenue58,574.00
Gross Profit-46,986.00
Operating Income-2.17M
Pretax Income-2.32M
Net Income-2.22M
EBITDA-2.03M
EBIT-2.17M
Earnings Per Share (EPS)-0.01

Balance Sheet

Kane Biotech Inc. holds 395,058.00 in cash and equivalents against 1.92M in total debt, resulting in a net debt position of 1.52M. Total book value stands at -9.86M, with working capital of -1.42M providing operational flexibility.

Cash & Cash Equivalents395,058.00
Total Debt1.92M
Net Debt1.52M
Equity (Book Value)-9.86M
Book Value Per Share-0.06
Working Capital-1.42M

Cash Flow

Kane Biotech Inc. produced -2.64M in operating cash flow over the past twelve months. After subtracting -90,047.00 in capital expenditures, free cash flow totaled -2.73M - equivalent to -0.02 per share.

Operating Cash Flow-2.64M
Capital Expenditures-90,047.00
Free Cash Flow-2.73M
FCF Per Share-0.02

Margins

Kane Biotech Inc. operates with a gross margin of -80.22, reflecting its pricing power and cost economics. The operating margin of -3,698.04 and net profit margin of -3,785.93 provide insight into operational efficiency.

Gross Margin-80.22
Operating Margin-3,698.04
Pretax Margin-3,963.11
Profit Margin-3,785.93
EBITDA Margin-3,469.46

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-49.00
FCF Yield-47.14

Stock Splits

Kane Biotech Inc.'s most recent stock split took place on March 13, 2017 with a 5:1 split ratio.

Last Split Date3/13/2017
Split Ratio5:1

Scores

Kane Biotech Inc. posts an Altman Z-Score of -47.94, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-47.94